Literature DB >> 3015954

Kinetics of platelet-activating factor 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced fibrinogen binding to human platelets.

E Kloprogge, M Mommersteeg, J W Akkerman.   

Abstract

Platelet-activating factor 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF-acether) triggers exposure of fibrinogen binding sites on platelets via binding to specific receptors. Comparison of [3H]PAF-acether binding with 125I-fibrinogen binding shows that the rate with which PAF-acether binds to a number of receptors and not the degree of receptor occupancy determines how much fibrinogen binds. At low concentrations of PAF-acether (0.1-1.0 nM) binding site exposure is incomplete and parallels the rate of formation of the PAF-acether-receptor complex. Fibrinogen binding then primarily depends on the concentration of PAF-acether. At a high concentration of PAF-acether (500 nM) binding site exposure is complete within 2-5 min. Fibrinogen binding then depends on the concentration of fibrinogen. Exposure of binding sites in the absence of fibrinogen leads to disappearance of accessible binding sites. At 500 nM PAF-acether, this disappearance is exponential in nature and shows the same characteristics after 5-15 min incubation with fibrinogen as after 60 min. Exposure of binding sites is then complete within 5 min and their disappearance is not disturbed by other processes. At 0.5 nM PAF-acether, the same characteristics are found after 60 min incubation with fibrinogen, but shorter incubation times reveal an ongoing binding site exposure that interferes with the disappearance process. These results demonstrate close coupling between the PAF-acether receptors and fibrinogen binding sites and indicate that the rate of formation of the PAF-acether-receptor complex is a major factor in the regulation of binding site exposure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3015954

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Protein kinase C and cyclic AMP regulate reversible exposure of binding sites for fibrinogen on the glycoprotein IIB-IIIA complex of human platelets.

Authors:  G van Willigen; J W Akkerman
Journal:  Biochem J       Date:  1991-01-01       Impact factor: 3.857

2.  Exposure of ligand-binding sites on platelet integrin alpha IIB/beta 3 by phosphorylation of the beta 3 subunit.

Authors:  G van Willigen; I Hers; G Gorter; J W Akkerman
Journal:  Biochem J       Date:  1996-03-15       Impact factor: 3.857

3.  Platelet-activating factor (PAF-acether) induces high- and low-affinity binding of fibrinogen to human platelets via independent mechanisms.

Authors:  E Kloprogge; J W Akkerman
Journal:  Biochem J       Date:  1986-12-01       Impact factor: 3.857

4.  The influence of cyclandelate on Ca++ translocation in human platelets.

Authors:  J W Akkerman; W E van den Hoven
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Regulation of platelet glycoprotein IIb/IIIa (integrin alpha IIB beta 3) function via the thrombin receptor.

Authors:  A N Giesberts; G van Willigen; E G Lapetina; J W Akkerman
Journal:  Biochem J       Date:  1995-07-15       Impact factor: 3.857

6.  4,4'-Di-isothiocyanatostilbene-2,2'-disulphonic acid ('DIDS') activates protein kinase C and Na+/H+ exchange in human platelets via alpha 2A-adrenergic receptors.

Authors:  R Nieuwland; G Van Willigen; J W Akkerman
Journal:  Biochem J       Date:  1993-07-15       Impact factor: 3.857

7.  Quantitative detection of platelet GPIIb-IIIa receptor antagonist activity using a flow cytometric method.

Authors:  L J Green; P Marder; S L Um; J A Jakubowski; J B Lawrence
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.